Global Gaucher Disease Market Worth USD 1.16 Billion by 2024 - Analysis, Technologies & Forecast Report 2016-2024 - Key Vendors: Genzyme, Shire, Actelion - Research and Markets

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/hzr4x9/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Gaucher Disease - Opportunity Analysis and Forecast to 2024" report to their offering.

The report estimates the Gaucher Disease market will be worth $1.16 billion by 2024.

Key Topics Covered:

  • Overview of GD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized GD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GD therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Benefits of this Report:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the GD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GD therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Track drug sales in the 7MM GD therapeutics market from 2014-2024.

Companies Mentioned:

  • Genzyme
  • Shire
  • Actelion
  • Protalix
  • Belrose Pharma

Report Structure:

1.1 List of Tables

1.2 List of Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Current Treatment Options

6 Unmet Needs Assessment and Oppportunity Analysis

7 R&D Strategies

8 Pipeline Assessment

9 Pipeline Valuation Analysis

10 Appendix

For more information visit http://www.researchandmarkets.com/research/hzr4x9/opportunityanalyze

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals